AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Gloria Lau
In 1997, when most companies in the contract research industry watched annual earnings grow more than 30%, one was busy making big changes.
That company, Pharmaceutical Product Development Inc., is one of the nation's largest contract research organizations. CROs take over extra drug testing that drug developers can't handle.
The firm enjoyed a 45% earnings gain in 1997. Yet it still decided to shake things up, leading some industry watchers to wonder: Why fix a business that didn't need fixing?
"Because the math didn't work," said Fred Eshelman, PPD's chief executive. "We diversified because . . . we didn't think the analysts' projected growth rates were sustainable in the long term."
Branching Out
Eshelman added two new arms to the company. In 1997, he added drug discoveryservices. A year later, so-called virtual partnerships were brought into the mix.